Regeneron Slumps As Its Biggest Moneymaker Flops Amid Ongoing Roche Rivalry
Investor's Business DailyRegeneron preannounced disappointing U.S. Eylea sales, while Exelixis issued light 2024 guidance. REGN stock and EXEL stock slumped.
The post Regeneron Slumps As Its Biggest Moneymaker Flops Amid Ongoing Roche Rivalry appeared first on Investor's …